The Coevolution Of The Single-Use And Biopharmaceutical Industries: Company And Industry Reflections From CPC

Single-use technology (SUT), specifically its evolution from clinical applications to commercial production, has made a remarkable impact on bioprocessing. SUT flexibility and sterility have helped to build a strong foundation for manufacturers to initiate production of many different drugs quickly and cost-effectively, including vaccines and cell and gene therapies (CGTs).

The pandemic reinforced that SUTs are “backbone” technologies that help exciting new therapies reach the market rapidly. CPC has been evolving and innovating alongside SUTs and the biopharmaceutical industry for the past 20 years. As a result, CPC’s biopharmaceutical-focused business and the solutions that we create to support SUTs have grown significantly.

Learn more about the evolution of CPC’s solutions for biopharmaceutical manufacturing and accelerating market entrance.